Rapport Therapeutics (NASDAQ:RAPP) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Rapport Therapeutics (NASDAQ:RAPP) from a sell rating to a hold rating in a research note published on Saturday.

A number of other research firms also recently commented on RAPP. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research report on Thursday, January 8th. HC Wainwright lifted their price target on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. The Goldman Sachs Group reiterated a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Finally, Citizens Jmp raised their target price on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $50.80.

Rapport Therapeutics Trading Down 1.6%

Shares of RAPP opened at $29.03 on Friday. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -10.71 and a beta of 1.63. The stock has a 50 day moving average of $28.30 and a 200-day moving average of $26.06. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $42.27.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $29.36, for a total transaction of $149,236.88. Following the sale, the chief executive officer owned 20,729 shares of the company’s stock, valued at $608,603.44. The trade was a 19.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Krishnaswamy Yeleswaram sold 2,840 shares of the stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $30.05, for a total value of $85,342.00. Following the completion of the transaction, the insider directly owned 296,991 shares of the company’s stock, valued at approximately $8,924,579.55. The trade was a 0.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 67,655 shares of company stock worth $1,941,612. 13.57% of the stock is owned by company insiders.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors have recently bought and sold shares of the stock. Capital International Investors increased its stake in Rapport Therapeutics by 30.7% during the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock valued at $101,055,000 after buying an additional 800,000 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Rapport Therapeutics by 23.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock worth $91,077,000 after acquiring an additional 579,903 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Rapport Therapeutics by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock valued at $55,151,000 after acquiring an additional 191,219 shares in the last quarter. Baker BROS. Advisors LP boosted its holdings in shares of Rapport Therapeutics by 181.2% in the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after acquiring an additional 997,000 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Rapport Therapeutics by 4.1% during the second quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company’s stock valued at $13,129,000 after acquiring an additional 45,063 shares during the period.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.